Icon of the Instituts for Quality and Efficiency in Health Care

IQWiG comments

IQWiG also comments on general topics, for example, draft laws or scientific methods. You can find the comments issued by the Institute and joint comments written in cooperation with other institutions on this page.

Comments (in chronological order):

2025-04-04

Scientific assessment of screening examinations for the detection of non-communicable diseases

In its comment, IQWiG welcomes the changes planned by the BMUV to the General Administrative Regulation and only suggests a few specific clarifications to the draft.

View comment

1 April 2025

Joint positions for better evidence in approval and benefit assessments

A key result of a workshop series of European regulatory authorities and HTA agencies: Drug studies should be designed in such a way that they address both regulatory questions and the essential research questions of benefit assessments.

to the position paper

2025-03-19

Evaluation of the EU rules on medical devices and in vitro diagnostics
Comment of Institute for Quality and Efficiency in Health Care (IQWiG) March 19th, 2025

2025-03-10

2025-02-25

2025-01-30

2025-01-17

2024-07-15

Position paper "Evidence base and easy/simple language" of the "Accessible Health Communication" department of the German Network for Health Literacy (DNGK).
Comment of 15 July 2024 by the Institute for Quality and Efficiency in Health Care (IQWiG) on the consultation version of 4 June 2024.

2020-06-03

Comment by IQWiG on the draft bill of the Federal Ministry of Health for a regulation on the procedural principles for the assessment of examination and treatment methods in outpatient health care services reimbursed by statutory health insurance and in hospitals (Regulation on the Procedure for the Assessment of Methods - MBVerfV) (German version)

2020-05-14

All clinical trial data on Covid-19 medicines and vaccines should be published on the day of marketing authorisation! Open letter to the European Medicines Agency

2020-02-17

IQWiG comment on the draft bill of the Federal Ministry of Health for a regulation on the procedure and requirements for testing the eligibility for reimbursement of digital health applications in statutory health insurance (Digitale-Gesundheitsanwendungen-Verordnung, DiGAV [Digital Health Applications Regulation]) (German Version)

2019-12-19

Joint open letter on access to clinical study reports

2019-09-16

Comments on 'Draft qualification opinion of clinically interpretable treatment effect measures based on recurrent event endpoints that allow for efficient statistical analyses' (EMA/CHMP/SAWP/291384/2019)

2019-06-27

Comments from IQWiG on 'Discussion paper: Use of patient disease registries for regulatory purposes – methodological and operational considerations' (EMA/763513/2018)

2019-06-18

IQWiG's comment on the Federal Government's draft for a law on the establishment of the German Implant Registry and further amendments to Social Code Book V (Implant Registry Establishment Act - EIRD) (German version)

2019-06-06

Comment by IQWiG on the draft by the Federal Ministry of Health (BMG) on a law for better health care through digitalization and innovation (Digital Health Care Act - DVG) (German Version)

2019-03-27

Stellungnahme des IQWiG zum Gesetzentwurf der Bundesregierung zum Entwurf eines Gesetzes für mehr Sicherheit in der Arzneimittelversorgung (GSAV) (German Version)

2019-02-16

Comments from IQWiG on 'Guideline on clinical investigation of medicinal products in the treatment of epileptic disorders' (CHMP/EWP/566/98 Rev.3)

2019-01-28

How the European Medicines Agency engages with medicine producers before they apply for authorisations to market their medicines in the EU - omments within the European Ombudsman’s inquiry OI/7/2017/KR - Public consultation

2012-12-05

IQWiG comment on the draft law of the Federal Government for advancing cancer screening and quality assurance using clinical cancer registries (Law on Cancer Screening and Registration – KFRG) Bundestag printed paper 17/11267 of 05.12.2012 (German version)

2012-10-25

Comment to AHRQ on: "Assessing confounding, the risk of bias and precision of observational studies of interventions or exposures: further development of the RTI Item Bank"

2012-09-13

Comment to AHRQ on: "A framework for assessing the strength of methodological recommendations for systematic review and meta-analysis"

2012-08-16

Comment on the proposal of the EU commission for a regulation of the European Parliament and of the Council on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC (German version)

2012-07-12

Comment on the draft of a law to implement the recommendations of the National Cancer Plan (Cancer Plan Implementation Law) (German version)

2012-06-26

IQWiG comment on the public hearing of the German Bundestag’s Committee on Health “Better guarantee of safety, efficacy and health benefit of medical devices”, Bundestag printed paper 17/8920, and “More safety for medical devices”, Bundestag printed paper 17/9932 (German version)

2012-06-06

Comment on the draft of a second law to Change Legislation on Medicinal Products and Other Regulations. (16th Amendment to the Medicinal Products Act [AMG]) (German version)

2012-03-07

Joint statement from IQWiG, GMDS and IBS-DR: "Importance of results from indirect comparisons"

2012-01-04

Comment on the draft of the Second law to Change Legislation on Medicinal Products and Other Regulations (16th Amendment to the AMG) (German version)

Print page